Access the full text.
Sign up today, get DeepDyve free for 14 days.
E. Braunwald (2012)
Unstable angina and non-ST elevation myocardial infarction.American journal of respiratory and critical care medicine, 185 9
(2017)
Updated coding algorithm for assessing Charlson Comorbidity Index using large hospital administrative data
Marc Cohen, C. Demers, E. Gurfinkel, A. Turpie, G. Fromell, S. Goodman, A. Langer, R. Califf, K. Fox, J. Premmereur, F. Bigonzi (1998)
Low-molecular-weight heparins in non–ST-segment elevation ischemia: the ESSENCE trialAmerican Journal of Cardiology, 82
S. Windecker, R. Hernández-Antolı́n, G. Stefanini, W. Wijns, J. Zamorano (2014)
Management of ST-elevation myocardial infarction according to European and American guidelines.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 10 Suppl T
J. Ferguson, R. Califf, E. Antman, Marc Cohen, C. Grines, S. Goodman, D. Kereiakes, A. Langer, K. Mahaffey, C. Nessel, P. Armstrong, Á. Avezum, P. Aylward, R. Becker, L. Biasucci, S. Borzak, J. Col, M. Frey, E. Fry, D. Gulba, S. Guneri, E. Gurfinkel, R. Harrington, J. Hochman, N. Kleiman, M. Leon, J. López-Sendón, C. Pepine, W. Rużyłło, S. Steinhubl, P. Teirstein, L. Toro-Figueroa, H. White (2004)
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.JAMA, 292 1
J. Collet, K. Huber, Marc Cohen, U. Zeymer, P. Goldstein, C. Pollack, J. Silvain, P. Henry, O. Varenne, D. Carrié, P. Coste, M. Angioi, H. Breton, G. Cayla, S. Elhadad, E. Teiger, E. Filippi, M. Aout, E. Vicaut, G. Montalescot (2013)
A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial).The American journal of cardiology, 112 9
Marc Cohen, P. Théroux, S. Borzak, M. Frey, H. White, W. Mieghem, F. Senatore, Joy Lis, R. Mukherjee, K. Harris, F. Bigonzi (2002)
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.American heart journal, 144 3
(2020)
Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI (RIGHT)
G. Merli, J. Groce (2010)
Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange.P & T : a peer-reviewed journal for formulary management, 35 2
D. Kolansky (2009)
Acute coronary syndromes: morbidity, mortality, and pharmacoeconomic burden.The American journal of managed care, 15 2 Suppl
E. Amsterdam, N. Wenger, R. Brindis, D. Casey, T. Ganiats, D. Holmes, A. Jaffe, H. Jneid, R. Kelly, M. Kontos, G. Levine, P. Liebson, D. Mukherjee, E. Peterson, M. Sabatine, R. Smalling, Susan Zieman (2014)
2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Journal of the American College of Cardiology, 64 24
C. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. Casey, M. Drazner, G. Fonarow, S. Geraci, T. Horwich, J. Januzzi, Maryl Johnson, E. Kasper, W. Levy, F. Masoudi, P. Mcbride, J. McMurray, J. Mitchell, Pamela Peterson, B. Riegel, F. Sam, L. Stevenson, W. Tang, E. Tsai, B. Wilkoff (2013)
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Journal of the American College of Cardiology, 62 16
J. Silvain, F. Beygui, O. Barthelemy, C. Pollack, Marc Cohen, U. Zeymer, K. Huber, P. Goldstein, G. Cayla, J. Collet, E. Vicaut, G. Montalescot (2012)
Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysisThe BMJ, 344
Zaher Fanari, Sandra Weiss, W. Weintraub (2015)
Cost Effectiveness of Antiplatelet and Antithrombotic Therapy in the Setting of Acute Coronary Syndrome: Current Perspective and Literature ReviewAmerican Journal of Cardiovascular Drugs, 15
Prof. Quittner, Prof. Souplet (2019)
SystemsSuperlinear Parabolic Problems
C. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. Casey, M. Drazner, G. Fonarow, S. Geraci, T. Horwich, J. Januzzi, Maryl Johnson, E. Kasper, W. Levy, F. Masoudi, P. Mcbride, J. McMurray, J. Mitchell, Pamela Peterson, B. Riegel, F. Sam, L. Stevenson, W. Tang, E. Tsai, B. Wilkoff (2013)
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.Circulation, 128 16
Kristopher Kline, C. Conti, D. Winchester (2015)
Historical perspective and contemporary management of acute coronary syndromes: from MONA to THROMBINS2Postgraduate Medicine, 127
L. Michalis, C. Katsouras, N. Papamichael, K. Adamides, K. Naka, J. Goudevenos, D. Sideris (2003)
Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial.American heart journal, 146 2
Premier Applied Sciences ®
M. Cohen, C. Demers, E. Gurfinkel, A. Turpie, G. Fromell, S. Goodman, A. Langer, R. Califf, K. Fox, J. Premmereur, F. Bigonzi, Jim Stephens, B. Weatherley (1997)
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.The New England Journal of Medicine, 337
Marc Cohen, P. Théroux, S. Borzak, M. Frey, H. White, W. Mieghem, F. Senatore, Joy Lis, R. Mukherjee, K. Harris, F. Bigonzi (2002)
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study☆☆☆★American Heart Journal, 144
P. Steg, Stefan James, D. Atar, Luigi Badano, C. Blömstrom-Lundqvist, M. Borger, Carlo Mario, Kenneth Dickstein, Gregory Ducrocq, Francisco Fernández-Avilés, A. Gershlick, Pantaleo Giannuzzi, S. Halvorsen, Kurt Huber, Peter Juni, Adnan Kastrati, Juhani Knuuti, Mattie Lenzen, K. Mahaffey, M. Valgimigli, Arnoud Hof, Petr Widimsky, D. Zahger (2012)
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.European heart journal, 33 20
Stefan Chairperson, D. Norway, L. Badano, M. Borger, A. Gershlick, S. Halvorsen, J. Knuuti, M. Lenzen, K. Mahaffey, Lars Sweden, S. James (2012)
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
B. Ibáñez, S. James, S. Agewall, M. Antunes, C. Bucciarelli-Ducci, H. Bueno, A. Caforio, F. Crea, J. Goudevenos, S. Halvorsen, G. Hindricks, A. Kastrati, M. Lenzen, E. Prescott, M. Roffi, M. Valgimigli, C. Varenhorst, P. Vranckx, P. Widimsky (2017)
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.Revista espanola de cardiologia, 70 12
Marc Cohen, C. Demers, E. Gurfinkel, A. Turpie, G. Fromell, Steven Goodman, Anatoly Langer, Robert Califf, K. Fox, J. Premmereur, F. Bigonzi (1998)
Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.The American journal of cardiology, 82 5B
D. Mark, P. Cowper, S. Berkowitz, L. Davidson-Ray, E. DeLong, A. Turpie, R. Califf, B. Weatherley, M. Cohen (1998)
Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarcCirculation, 97 17
M. Zeitouni, M. Kerneis, Tarek Nafee, J. Collet, J. Silvain, G. Montalescot (2018)
Anticoagulation in Acute Coronary Syndrome-State of the Art.Progress in cardiovascular diseases, 60 4-5
E. Antman, D. Anbe, P. Armstrong, Eric Bates, L. Green, M. Hand, J. Hochman, H. Krumholz, F. Kushner, G. Lamas, C. Mullany, J. Ornato, D. Pearle, M. Sloan, Sidney Smith (2004)
ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients WiThe Canadian journal of cardiology, 20 10
E. Benjamin, S. Virani, C. Callaway, A. Chamberlain, Alexander Chang, Susan Cheng, Stephanie Chiuve, M. Cushman, F. Delling, R. Deo, S. Ferranti, J. Ferguson, M. Fornage, C. Gillespie, C. Isasi, M. Jimenez, L. Jordan, S. Judd, D. Lackland, J. Lichtman, L. Lisabeth, Simin Liu, C. Longenecker, P. Lutsey, J. Mackey, D. Matchar, K. Matsushita, M. Mussolino, K. Nasir, M. O’Flaherty, L. Palaniappan, A. Pandey, D. Pandey, M. Reeves, M. Ritchey, C. Rodriguez, Gregory Roth, W. Rosamond, Uchechukwu Sampson, G. Satou, Svati Shah, Nicole Spartano, D. Tirschwell, C. Tsao, Jenifer Voeks, J. Willey, J. Wilkins, Jason Wu, Heather Alger, Sally Wong, P. Muntner (2018)
Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart AssociationCirculation, 137
G. Levine, E. Bates, J. Blankenship, S. Bailey, J. Bittl, B. Cercek, C. Chambers, S. Ellis, R. Guyton, S. Hollenberg, U. Khot, R. Lange, L. Mauri, R. Mehran, I. Moussa, D. Mukherjee, B. Nallamothu, H. Ting, A. Jacobs, Jeffrey Anderson, N. Albert, M. Creager (2011)
ACCF/AHA/SCAI Practice Guideline 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
Glenn Levine, Eric Bates, James Blankenship, Steven Bailey, J. Bittl, Bojan Cercek, Charles Chambers, Stephen Ellis, Robert Guyton, Steven Hollenberg, U. Khot, Richard Lange, Laura Mauri, Roxana Mehran, I. Moussa, D. Mukherjee, B. Nallamothu, Henry Ting (2011)
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.Circulation, 124 23
BackgroundEnoxaparin and unfractionated heparin (UFH) are guideline-recommended anticoagulants for patients with acute coronary syndrome (ACS), including unstable angina (UA) and myocardial infarction with (STEMI) or without ST-segment elevation (NSTEMI). Prior efficacy and safety evidence are mainly from clinical trials. Economic data are insufficient. This study examined the differences in utilization, effectiveness, safety, and costs in treating ACS between enoxaparin and UFH monotherapy using real-world data.MethodsUsing data from 859 US hospitals, inpatients ≥ 18 years of age with a diagnosis of an initial episode of ACS between 2010 and 2016 were identified. Outcomes included 30-day risk of non-fatal myocardial infarction (MI), recurrent angina, in-hospital mortality, composite ischemic complication (having MI/recurrent angina/death), major bleeding, and costs. Multivariable regression was used to compare outcomes between enoxaparin and UFH monotherapy.ResultsAmong 1,048,053 eligible patients (UA: 219,259; NSTEMI: 582,134; STEMI: 246,660), the prevalence of enoxaparin monotherapy was 12.0%, 13.9%, and 5.1%, and the prevalence of UFH monotherapy was 45.1%, 43.1% and 59.8%, for UA, NSTEMI, and STEMI patients, respectively. Enoxaparin was associated with a lower risk of ischemic complications and death among NSTEMI, but not in UA or STEMI patients, and with a lower risk of major bleeding in all patients. Cost savings per patient during index admission and 30-day follow-up for enoxaparin over UFH was $2972 for UA, $2475 for NSTEMI, and $3050 for STEMI.ConclusionsEnoxaparin was associated with a lower risk of ischemic complications (including death), lower costs, and better safety than UFH among NSTEMI patients. Improving upstream selection of anticoagulants in appropriate populations may help optimize clinical outcomes and costs.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Jun 23, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.